AWM Investment Company Inc. continued to hold its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the first quarter, according to its most recent filing with the SEC. The firm owned 765,105 shares of the medical instruments supplier’s stock at the end of the first quarter. LeMaitre Vascular makes up approximately 3.5% of AWM Investment Company Inc.’s portfolio, making the stock its 5th largest position. AWM Investment Company Inc. owned about 4.11% of LeMaitre Vascular worth $18,845,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. American International Group Inc. increased its stake in shares of LeMaitre Vascular by 7.0% in the first quarter. American International Group Inc. now owns 8,310 shares of the medical instruments supplier’s stock valued at $205,000 after buying an additional 545 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in shares of LeMaitre Vascular during the fourth quarter valued at about $238,000. Bank of Montreal Can increased its stake in shares of LeMaitre Vascular by 32.2% in the first quarter. Bank of Montreal Can now owns 10,483 shares of the medical instruments supplier’s stock valued at $258,000 after buying an additional 2,552 shares in the last quarter. A.R.T. Advisors LLC acquired a new stake in shares of LeMaitre Vascular during the fourth quarter valued at about $266,000. Finally, Blair William & Co. IL increased its stake in shares of LeMaitre Vascular by 6.9% in the first quarter. Blair William & Co. IL now owns 11,977 shares of the medical instruments supplier’s stock valued at $295,000 after buying an additional 768 shares in the last quarter. 66.33% of the stock is owned by institutional investors.
LeMaitre Vascular, Inc. (LMAT) traded up 2.64% on Monday, reaching $27.97. The company’s stock had a trading volume of 90,829 shares. The stock’s 50 day moving average price is $30.35 and its 200 day moving average price is $25.51. The company has a market cap of $526.09 million, a P/E ratio of 46.69 and a beta of 0.65. LeMaitre Vascular, Inc. has a 12 month low of $13.52 and a 12 month high of $33.22.
LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, May 4th. The medical instruments supplier reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.03. LeMaitre Vascular had a net margin of 12.52% and a return on equity of 13.36%. The company had revenue of $24.10 million for the quarter, compared to analysts’ expectations of $23.48 million. The business’s quarterly revenue was up 18.7% compared to the same quarter last year. Equities research analysts forecast that LeMaitre Vascular, Inc. will post $0.70 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 8th. Shareholders of record on Wednesday, May 24th were issued a $0.055 dividend. This represents a $0.22 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date was Monday, May 22nd. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 36.67%.
LMAT has been the topic of several research reports. First Analysis began coverage on LeMaitre Vascular in a research report on Tuesday, March 21st. They issued an “overweight” rating and a $29.00 target price on the stock. Stifel Nicolaus raised their target price on LeMaitre Vascular from $25.00 to $29.00 and gave the company a “buy” rating in a report on Friday, April 28th. Craig Hallum assumed coverage on LeMaitre Vascular in a report on Tuesday, June 6th. They issued a “hold” rating and a $31.00 target price on the stock. Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 22nd. Finally, Canaccord Genuity restated a “buy” rating and set a $28.00 target price on shares of LeMaitre Vascular in a research report on Thursday, April 27th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $27.00.
In other news, VP Michael T. Wijas sold 2,346 shares of the stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $31.42, for a total transaction of $73,711.32. Following the sale, the vice president now owns 3,584 shares in the company, valued at $112,609.28. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider David B. Roberts sold 44,340 shares of the stock in a transaction that occurred on Thursday, May 4th. The shares were sold at an average price of $31.14, for a total transaction of $1,380,747.60. Following the sale, the insider now owns 46,945 shares in the company, valued at approximately $1,461,867.30. The disclosure for this sale can be found here. In the last 90 days, insiders sold 317,805 shares of company stock worth $9,910,332. Corporate insiders own 23.70% of the company’s stock.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with our FREE daily email newsletter.